212 related articles for article (PubMed ID: 20842591)
61. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
[TBL] [Abstract][Full Text] [Related]
62. Low-grade gliomas.
Ruiz J; Lesser GJ
Curr Treat Options Oncol; 2009 Aug; 10(3-4):231-42. PubMed ID: 19381819
[TBL] [Abstract][Full Text] [Related]
63. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
64. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
[TBL] [Abstract][Full Text] [Related]
65. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Combs SE; Bischof M; Welzel T; Hof H; Oertel S; Debus J; Schulz-Ertner D
J Neurooncol; 2008 Sep; 89(2):205-10. PubMed ID: 18461281
[TBL] [Abstract][Full Text] [Related]
66. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
[TBL] [Abstract][Full Text] [Related]
67. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
68. Survival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomas.
Aktan M; Koc M; Kanyilmaz G
Ann Transl Med; 2015 Nov; 3(20):304. PubMed ID: 26697464
[TBL] [Abstract][Full Text] [Related]
69. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
70. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
[TBL] [Abstract][Full Text] [Related]
71. Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide.
Ezaki T; Sasaki H; Hirose Y; Miwa T; Yoshida K; Kawase T
Mol Med Rep; 2011; 4(6):1101-5. PubMed ID: 21874248
[TBL] [Abstract][Full Text] [Related]
72. The future of high-grade glioma: Where we are and where are we going.
Le Rhun E; Rhun EL; Taillibert S; Chamberlain MC
Surg Neurol Int; 2015; 6(Suppl 1):S9-S44. PubMed ID: 25722939
[TBL] [Abstract][Full Text] [Related]
73. Stereotactic Radiosurgery for the Treatment of Recurrent High-grade Gliomas: Long-term Follow-up.
Sallabanda K; Yañez L; Sallabanda M; Santos M; Calvo FA; Marsiglia H
Cureus; 2019 Dec; 11(12):e6527. PubMed ID: 31911881
[TBL] [Abstract][Full Text] [Related]
74. Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage.
Lin X; Daras M; Pentsova E; Nolan CP; Gavrilovic IT; DeAngelis LM; Kaley TJ
Neurooncol Pract; 2017 Mar; 4(1):24-28. PubMed ID: 31044081
[TBL] [Abstract][Full Text] [Related]
75. Anaplastic astrocytoma.
Grimm SA; Pfiffner TJ
Curr Treat Options Neurol; 2013 Jun; 15(3):302-15. PubMed ID: 23543397
[TBL] [Abstract][Full Text] [Related]
76. High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.
Pöhlmann J; Weller M; Marcellusi A; Grabe-Heyne K; Krott-Coi L; Rabar S; Pollock RF
Front Oncol; 2024; 14():1368606. PubMed ID: 38571509
[TBL] [Abstract][Full Text] [Related]
77. Newly diagnosed high-grade gliomas.
Giglio P; Villano JL
Curr Treat Options Neurol; 2010 Jul; 12(4):309-20. PubMed ID: 20842590
[TBL] [Abstract][Full Text] [Related]
78. Glioma diagnosis and comprehensive management during COVID-19 pandemic: A proposed algorithm.
Cecilia C; Ardiansyah D
J Neurosci Rural Pract; 2023; 14(3):395-398. PubMed ID: 37692817
[TBL] [Abstract][Full Text] [Related]
79. Glioblastoma - treatment and obstacles.
Cantidio FS; Gil GOB; Queiroz IN; Regalin M
Rep Pract Oncol Radiother; 2022; 27(4):744-753. PubMed ID: 36196416
[TBL] [Abstract][Full Text] [Related]
80. Refractory anaplastic astrocytoma responsive to PCV in combination with bevacizumab.
Swaminathan A; Lightner DD; Pittman T; Horbinski C; Villano JL
Case Rep Clin Pathol; 2015 Sep; 2(3):17-22. PubMed ID: 38222924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
